Huperzine A for Cognitive Function
Trials in Alzheimer disease show cognitive improvement, but methodological quality is poor and healthy-adult data is minimal.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 200-400 mcg/day huperzine A in two divided doses with food, for Alzheimer-type indications; 50-200 mcg/day is the range used recreationally
- Expected timeframe
- 8-12 weeks
Protocol
- form
- Isolated alkaloid; a licensed Alzheimer medicine in China and a supplement elsewhere
- duration
- 8-24 weeks in the trials; cycle rather than take indefinitely
- co factor
- Take with food. Evidence is mixed and splits by population. In Alzheimer disease, systematic reviews of Chinese randomised trials report improvements in MMSE and activities of daily living with 200-400 mcg/day, with effect sizes comparable to donepezil - but reviewers consistently note poor methodological quality, small samples, and publication bias favouring positive results from a single country, so the finding is not considered established internationally. In healthy adults, evidence is far thinner: one small study in adolescents reported improved memory, but there is no robust trial showing cognitive enhancement in healthy people. Cholinesterase inhibition helps where cholinergic neurons are failing; it is not a general nootropic.
- titration
- Increase gradually to 200 mcg twice daily if targeting the doses used in dementia trials. Do not exceed 400 mcg/day
- starting dose
- 50 mcg once daily with food to assess tolerance
Evidence
What the studies say
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii MS, Walsh S, Little JT +6 more
The primary outcome, change in ADAS-Cog at week 16, did not differ from placebo.
Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Yang G, Wang Y, Tian J +1 more
Huperzine A improved MMSE and activities of daily living scores versus placebo, but all trials had unclear or high risk of bias.
Safety
Caveats
Progressive memory loss, difficulty with familiar tasks or personality change needs medical assessment - reversible causes including B12 deficiency, thyroid disease, depression, sleep apnoea and medication effects are treatable. Do not self-treat dementia; prescribed cholinesterase inhibitors are given with monitoring for good reason. Safety ceiling: do not exceed 400 mcg/day, and never combine with donepezil, rivastigmine or galantamine - additive cholinergic toxicity can cause bradycardia, seizures, bronchospasm and cholinergic crisis. Avoid with beta-blockers, anticholinergics, and neuromuscular blockers; stop two weeks before surgery and tell your anaesthetist. Contraindicated in epilepsy, asthma or COPD, peptic ulcer disease, bradycardia or heart block, and urinary obstruction. No safety data in pregnancy or breastfeeding - avoid in both, and in children. Long-term safety beyond a year is unestablished.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.